BioTime (BTIM.PK)'s CEO Michael West Presents 12 New ACTCellerateTM Cell Lines and New PureStemTM Products Slated for Launch in 2011 at GTCBIO Stem Cell Conference Today
10/22/2010 10:06:43 AM
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE Amex:BTIM) announced that the Company’s CEO Dr. Michael West will present data today relating to 12 new cell lines, differentiation kits, and cell culture media at the GTCbio 4th Advances in Stem Cell Discovery and Development Conference in San Francisco, California. Dr. West’s presentation titled: “Fate Space Screening of Clonal Human ES-derived Embryonic Progenitor Cell Lines” will include a discussion of the Company’s proprietary bank of more than 140 diverse human cell types made from human embryonic stem cells, the company’s screening technology for discovering means of manufacturing human cell types, and the potential use of these cells for diverse new therapeutics and drug discovery.
comments powered by